Zai Lab/$ZLAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Ticker
$ZLAB
Sector
Primary listing
Employees
1,869
Headquarters
Website
Zai Lab Metrics
BasicAdvanced
$3.6B
-
-$2.03
1.03
-
Price and volume
Market cap
$3.6B
Beta
1.03
52-week high
$44.34
52-week low
$20.17
Average daily volume
747K
Financial strength
Current ratio
3.119
Quick ratio
2.508
Long term debt to equity
1.428
Total debt to equity
24.175
Interest coverage (TTM)
-60.26%
Profitability
EBITDA (TTM)
-233.854
Gross margin (TTM)
8.73%
Net profit margin (TTM)
-49.68%
Operating margin (TTM)
-57.73%
Revenue per employee (TTM)
$230,000
Management effectiveness
Return on assets (TTM)
-14.35%
Return on equity (TTM)
-28.41%
Valuation
Price to revenue (TTM)
7.8
Price to book
4.43
Price to tangible book (TTM)
4.79
Price to free cash flow (TTM)
-14.446
Free cash flow yield (TTM)
-6.92%
Free cash flow per share (TTM)
-2.21
Growth
Revenue change (TTM)
32.56%
Earnings per share change (TTM)
-33.76%
3-year revenue growth (CAGR)
32.92%
3-year earnings per share growth (CAGR)
-28.39%
What the Analysts think about Zai Lab
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Bulls say / Bears say
Total revenues climbed 9% year-over-year to $110.0 million in Q2 2025, and Zai Lab maintained its full-year revenue guidance of $560 million to $590 million, signaling steady business growth (Business Wire).
ZL-1310 (DLL3 ADC) results presented at ASCO 2025 showed a 67% overall response rate at all doses and 79% at 1.6 mg/kg in second-line ES-SCLC, with a favorable safety profile, setting up the asset for a pivotal trial in H2 2025 (Business Wire).
Operating loss fell 28% year-over-year to $54.9 million, and adjusted operating loss narrowed by 37% to $34.2 million, keeping Zai Lab on course for adjusted profitability in Q4 2025 (Business Wire).
ZEJULA sales dropped to $41.0 million in Q2 2025 from $45.0 million a year earlier, reflecting growing competition in the PARP inhibitor market and potential pressure on Zai Lab’s ovarian cancer business (Business Wire).
Despite operational gains, Zai Lab posted a net loss of $40.7 million in Q2 2025, highlighting ongoing cash burn and questions about reaching full-year adjusted profit goals (Business Wire).
China’s intensified anti-corruption campaign in healthcare could hurt drug sales and investor confidence, possibly affecting Zai Lab’s commercial performance in its main market (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Zai Lab Financial Performance
Revenues and expenses
Zai Lab Earnings Performance
Company profitability
Zai Lab News
AllArticlesVideos
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback
Benzinga5 days ago
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
Business Wire2 weeks ago
Zai Lab Announces Participation in Investor Conferences in September 2025
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zai Lab stock?
Zai Lab (ZLAB) has a market cap of $3.6B as of September 16, 2025.
What is the P/E ratio for Zai Lab stock?
The price to earnings (P/E) ratio for Zai Lab (ZLAB) stock is 0 as of September 16, 2025.
Does Zai Lab stock pay dividends?
No, Zai Lab (ZLAB) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Zai Lab dividend payment date?
Zai Lab (ZLAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Zai Lab?
Zai Lab (ZLAB) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.